Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19829315 | 0.88 | TSHR (0.69) | TSHRALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL12471546 | 0.87 | TSHR (0.58) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12471154 | 0.84 | TSHR (0.58) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10724061 | 0.83 | TSHR (0.78) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10720174 | 0.81 | TSHR (0.63) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL24495698 | 0.81 | TSHR (0.66) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12471398 | 0.78 | HRH3 (0.57) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12471396 | 0.78 | HRH3 (0.57) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12911161 | 0.78 | TSHR (0.69) | TSHRKMT2ANPC1RAB9AGLA | |
| SCHEMBL3660045 | 0.77 | TSHR (0.69) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034869-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180028511-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA | 2018-02-01 | — | — | US | disclosed |
| US-9808449-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160263093-A1 | S1P modulating agents | BIOGEN MA INC. | 2016-09-15 | — | — | US | disclosed |
| US-9340527-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140371209-A1 | S1P Modulating Agents | BIOGEN MA INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371209-A1 | S1P Modulating Agents | S1PR2, S1PR1, S1PR3 | TSHR 259/4885CYP1A2 4239/4885CYP3A4 4700/4885 |
| US-10034869-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | TSHR 659/4885CYP1A2 2926/4885CYP3A4 3333/4885 |
| US-20180028511-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | TSHR 521/4885CYP1A2 2647/4885CYP3A4 3438/4885 |
| US-20160263093-A1 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | TSHR 521/4885CYP1A2 2647/4885CYP3A4 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.